Overview

Depression Drugs Market Introduction: Depression Drugs Market is estimated to value over USD 14 billion by 2027 end and register a CAGR of over 1.8% during the forecast period 2020 to 2027. Antidepressants or depression drugs refer to the broad range of medications that are consumed by patients for the treatment of mental disorders such as depression and social anxiety. They are especially formulated to balance the functioning of neurotransmitters such as controlling the emotions and mood of the patient and serotonin in the brain. Depression and other mental ailments are best described as the mental state that is devoid of positive emotions, mood swings and a number of physical, cognitive, emotional and behavioral symptoms. Depression drugs can help in providing relief in the symptoms of seasonal affective disorder, anxiety and dysthymia. Certain antidepressant drugs include the use of Monoamine Oxidase Inhibitors (MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs) and atypical antidepressants. These drugs produce good results when consumed along with regular therapeutic sessions. Market study demonstrates that there is a growing pattern in depression-related disorders on a global scale and that such patterns have been registered to drive augment the market growth in the forecast time frame. Depression in adults and adolescents alike, have seen a rise owing to several reasons such as inadequate dietary food habits, social alienation and work life imbalance. Moreover, the growing geriatric population on a global scale, is afflicted with social isolation from friends and family alike, as well as other health related issues. All these factors combined, have anticipated an expansion in the depression drugs market size in the forecast period. However, it is to be observed, that there is growing awareness about depression as a psychological illness and the methods and strategies which are undertaken to cure it, which has led to the increased adoption of these drugs in patients belonging to all groups. In addition, the prevalence of novel techniques for the cultivation of antidepressants with the least number of side effects with prolonged positive results as well as an adoption and positive outlook on these medications has been expected to heighten the market growth in the forecast timeline. For example, psychedelics like ketamine are extensively viewed as beneficial easing the symptoms of depression and offering a remedy. The depressive disorder segment is bifurcated into panic disorder, major depressive disorder, generalized anxiety disorder, obsessive compulsive disorder and others. Major depressive disorder emerges as the primary factor behind the market growth as a number of people are afflicted with this disorder owing to a rise in the levels of stress. Having said that, obsessive compulsive disorder is among the most rapidly growing segment. The market is fragmented into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors etc. Among this segment, it is the serotonin-norepinephrine reuptake inhibitors that has brought the largest revenue. Prominent players in the Market includes: Allergan, Plc, Novartis International AG, Lupin Pharmaceuticals, Inc., Abbott Laboratories and Janssen Pharmaceuticals, Inc., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, Pfizer. Depression Drugs Market Segmentation: By Depressive Disorder Major Depressive Disorder

Obsessive-Compulsive Disorder

Generalized Anxiety Disorder

Panic Disorder

Others By Product Tricyclic Antidepressants

Selective Serotonin Reuptake Inhibitors

Serotonin- Norepinephrine Reuptake Inhibitors

Monoamine Oxidase Inhibitors

Serotonin Antagonist & Reuptake Inhibitors

Others By Region North America

Europe

Asia Pacific

Latin America

Middle East & Africa FutureWise Key Takeaways: Growth prospects

SWOT analysis

Key trends

Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global depression drugs market by depressive disorder, by product, and by region

To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

To evaluate and forecast micro-markets and the overall market

To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa

To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement

The customization Mobility Care offered are free of charge with purchase of any license of the report

You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com